- Annual Meeting
- Practice Resources
- Study Groups
- ISOO – Oral Oncology
MASCC Hemostasis Study Group
Study Group Minutes
Mission and Goals
The mission of the Hemostasis Study Group is to provide guidance and guidelines to healthcare providers regarding bleeding and clotting complications in cancer patients from diagnosis to the end of life. The goals of the group are (1) an increased awareness of abnormalities in the coagulation system at the time of cancer diagnosis, through treatment, and at the end of life, and (2) an increased availability of evidence-based treatment to patients with bleeding or clotting complications during treatment and at the end of life. To these ends, the Group has set the following objectives:
The Clinical Course of Venous Thromboembolism May Differ With Cancer Site
Incidental Venous Thromboembolism in Cancer Patients on Routine CT Scans
Romiplostim for the Management of Chemotherapy-Induced Thrombocytopenia
Outpatient Management of Pulmonary Embolism in Cancer
2017 Annual Meeting Workshop, June 22, Washington, DC
This workshop will be offered jointly by the following MASCC Study Groups: Education; Hemostasis.
Recent Member Publications
FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence. Jimenez-Fonseca P, Carmona-Bayonas A, Calderon C, Fontcuberta Boj J, Font C, Lecumberri R et al. Clin Transl Oncol. 2017 Feb 27. [Epub ahead of print]
Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism. Trujillo-Santos J, Martos FM, Font C, Farge-Bancel D, Rosa V, Lorenzo A et al. Heliyon. 2017 Jan 16;3(1):e00229. Free PMC Article
Prospective cohort study of cancer patients diagnosed with incidental venous thromboembolism on routine computed tomography scans. Escalante CP, Gladish GW, Qiao W, Zalpour A, Assylbekova B, Gao S et al. Support Care Cancer. 2017 Jan 9. [Epub ahead of print]
Prognostic value of computed tomography pulmonary angiography indices in patients with cancer-related pulmonary embolism: Data from a multicenter cohort study. Plasencia-Martínez JM, Carmona-Bayonas A, Calvo-Temprano D, Jiménez-Fonseca P, Fenoy F, Benegas M, Sánchez M, Font C et al. Eur J Radiol. 2017 Feb;87:66-75.
Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study. Font C, Carmona-Bayonas A, Beato C, Reig Ò, Sáez A, Jiménez-Fonseca P et al; Asociación para la Investigación de la Enfermedad Tromboembólica de la región de Murcia. Eur Respir J. 2017 Jan 4;49(1).
Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial. Lu H, Champlin RE, Popat U, Pundole X, Escalante CP, Wang X et al. Bonekey Rep. 2016 Oct 19;5:843.
The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site. Mahé I, Chidiac J, Bertoletti L, Font C, Trujillo-Santos J, Peris M et al; RIETE investigators. Am J Med. 2017 Mar;130(3):337-347.
Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism. Peris M, Jiménez D, Maestre A, Font C, Tafur AJ, Mazzolai L et al; RIETE Investigators. Eur Respir J. 2016 Nov;48(5):1360-1368.
On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism. Carmona-Bayonas A, Font C, Jiménez-Fonseca P, Fenoy F, Otero R, Beato C et al; Asociación de Investigación de la Enfermedad Tromboembólica de la Región de Murcia. Thromb Res. 2016 Jul;143:76-85.
Home management of acute medical complications in cancer patients: a prospective pilot study. Font C, Fernández-Avilés F, Calderon C, García-Fernández T, Arab N, Pineda E, et al.Support Care Cancer 2016 May;24(5):2129-37.
Patients' Experiences of LIving with CANcer associated thrOmbosis in Spain (PELICANOS). Font C, Garcia-Fernandez T, Nelson A, Prout H, Noble S. Thromb Res. 2016 Apr;140 Suppl 1:S199.
Phlegmasia cerulea dolens and multiple recurrent thrombotic events as the presenting feature of EML4-ALK translocated non-small cell lung cancer. Fernandez-Martinez A, Font C, Selvi M, Viladot M, Paré L, Galván P. et al. Cancer Treatment Communications, 6(2016):4-7.
Prediction of serious complications in patients with seemingly stable febrile neutropenia: Validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M, et al. J Clin Oncol. 2015 Feb 10;33(5):465-71.
[Pulmonary embolism in patients with cancer: foundations of the EPIPHANY study] Font C, Carmona-Bayonas A, Plasencia JM, Calvo-Temprano D, Sánchez M, Jiménez-Fonseca P et al; en representación de los Investigadores del Proyecto EPIPHANY. Med Clin (Barc). 2015 Jan;144 Suppl 1:31-7. Spanish.
Clinical guide SEOM on venous thromboembolism in cancer patients. Muñoz Martín AJ, Font Puig C, Navarro Martín LM, Borrega García P, Martín Jiménez M; Spanish Society for Medical Oncology. Clin Transl Oncol. 2014 Dec;16(12):1079-90.
Bacteremia in adult cancer patients with apparently stable febrile neutropenia: data from a cohort of 692 consecutive episodes from a single institution. Carmona-Bayonas A, Fonseca PJ, Font C, Martínez-García J, Torrella F, Urrego E, et al. J Community Support Oncol. 2014 Sep;12(9):312-20.
Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G. 2014 May;22(5):1217-22.
Outpatient management of pulmonary embolism in cancer: Data on a prospective cohort of 138 consecutive patients. Font C, Carmona-Bayonas A, Fernández-Martinez A, Beato C, Vargas A, Gascon P, Otero R. J Natl Compr Canc Netw. 2014 Mar 1;12(3).
What's New in the Management of Blood Clots for Cancer Patients
Please contact the Study Group Chairs above with your questions.